ERBB2 and breast cancer: It is, therefore, important to: 1) further elucidate the HER2-mediated pathway that contributes to AI resistance, particularly characteristics associated with AI resistant breast cancer cells; and 2) identify other potential factors involved that may serve as novel molecular biomarkers and therapeutic targets.